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1.0 Executive Summary 
Cytomegalovrius (CMV) retinitis is a common symptom of vision loss found in 20-30% of all 
acquired immunodeficiency syndrome (AIDS) sufferers.  While there are no drugs that can 
cure permanent retinal damage by CMV, the drug ganciclovir has demonstrated efficacy 
against human cytomegalovirus infections and has been considered a first-line therapy in the 
treatment of sight-threatening cytomegalovirus infection in immune-compromised patients.   
The FDA-approved Vitrasert® implant, which is inserted at a localized region of the eye, is the 
current method of delivering ganciclovir intraocularly to patients with CMV.  The Vitrasert® 
is a disc-like reservoir microcapsule that encapsulates ganciclovir in a polymer-based system.  
Maintaining a constant level of drug in the infected eye region is an important requirement in 
the design of this implant.  The more constant the rate of drug release from the microcapsule, 
the more effective the drug will be.  The objective of our model is to measure the diffusion of 
the ganciclovir release from the Vitrasert® into the surrounding tissue and to ensure toxic 
levels of the drug is not sustained.  To accomplish this objective, the implant is simplified via 
axis-symmetry from a 3-D cylinder into a 2-D rectangle with homogeneous material 
properties, while the skin is reduced to a quarter-circle around our capsule.  With our model, 
we are able to optimize the characteristics of the microcapsule to facilitate near constant drug 
release, which would be beneficial for many pharmaceuticals working with drug release from 
reservoir microcapsules.  
 
Key Words: cytomegalovirus retinitis, ganciclovir, Vitrasert®, microcapsule, constant release 
rate 
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2.0 Introduction  
2.1 Background and Importance 
Cytomegalovirus (CMV) Retinitis, a member of the herpes virus family, 
is one of the most common causes of vision loss in patients with acquired 
immunodeficiency syndrome or otherwise known as AIDS.
2 Since AIDS 
is caused by the human immunodeficiency virus (HIV) which attacks the 
body’s immune system, eye infections is a common symptom.   
 
Cytomegalovirus is found in about 20-30% of AIDS sufferers and causes a 
serious impairment in sight.
2 CMV causes vision loss in one of the following manners:   
through the direct attack of the retinal tissue which destroys the cells needed for vision stimuli, 
or causing the patient to be more susceptible to retina detachments that are difficult to repair.  
Retina detachments can also cause cataracts to develop compounding the severity of vision 
loss in patients with CMV.   
Modern Drug Delivery
1
 
Currently, there exists no cure for the permanen t  v i s i o n d am a g e  c a u s e d  b y  C M V.   T h e r e 
exists, however, several effective medications to treat this disease.  One common treatment is 
the incorporate of ganciclovir into a reservoir microcapsule, which is then implanted into a 
region of tissue close to the infection site.  The drug will diffuse into the localized surrounding 
tissue from the implant allowing the drug to be administrated for a prolonged period of time. 
 
Ganciclovir is a nucleoside analogue with antiviral activity against human cytomegalovirus 
and herpes simplex virus types 1 and 2.  For patients without renal failure, ganciclovir should 
be administered as a 1-hour intravenous infusion at a dosage of 2.5 mg/kg every 8 hours or 5 
mg/kg every 12 hours for a duration of 14 to 21 days.  A maintenance regiment of 5 
mg/kg/day is recommended to prevent recurrences of cytomegalovirus infections.  Those 
suffering with impaired renal function should receive reduced ganciclovir dosage.  Ganciclovir 
administered at concentrations greater than 40 mg/L (155 μmol/L) is associated with local 
degeneration of retinal cells and disorganization of retinal layers marking the minimum 
toxicity bounds. 
 
The Vitrasert® is a FDA-approved reservoir microcapsule with encapsulated ganciclovir that 
has been prescribed to treat patients with CMV.  The implant is inserted surgically in the 
posterior segment of the eye that is located in the proximity of the site of infection; releasing an Optimizing Release from Reservoir Microcapsules   5 
 
effective drug dosage for longer periods of time without damage to healthy tissues.  The 
current Vitrasert® can continue to release ganciclovir between six to eight months.  When the 
drug is depleted, the implant can be removed and a new Vitrasert® can be inserted.  In a study 
done by Bausch & Lomb Surgical’s Phase III trial of 188 AIDS patients with CMV Retinitis, 
the Vitrasert® implant has shown to delay the disease progression significantly.
3
 
2.2 Microcapsules 
Microcapsules are used in drug delivery because they allow controlled release rates due to slow 
diffusion.  There are three main types of microcapsule release: reservoir diffusion, monolithic 
diffusion, and biodegradable microcapsule release.  For our report we will focus on the first 
type: reservoir diffusion, which consists of a small reservoir of suspended drugs encapsulated 
by a spherical polymer matrix (See Figure 1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
W e  c h o s e  t h i s  p a r t i c u l a r  t y p e  o f  m i c r o c a p s u l e  b e c a u s e  i t  g i v e s  u s  r e l a t i v e l y  p r e d i c t a b l e  
diffusion profiles and is adjustable for various treatment needs.  Using COMSOL, 
computational fluid dynamic software and inputting known properties for ganciclovir diffusion 
through the polymer layer, we can vary the capsule’s geometry and concentration in the 
reservoir to obtain a release profile suitable for the patient. 
Figure 1: Diffusion of drug release out of polymer. The polymer encapsulating the drug does not degrade which is a 
feature of a reservoir microcapsule. 
4 
 
In general, we want a release profile that is slow in order to sustain delivery of drug for at least 
several months while maintaining a drug concentration between the MEC (Minimum effective 
concentration) and MTC (Minimum toxic concentration); these values vary with different 
drugs.
5
 
3.0 Design Objectives 
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In our model, we decided to study the rates of drug release from reservoir microcapsules and 
apply these findings to optimize the rate of ganciclovir released from the Vitrasert® into the 
site of infection.  Our main design objectives are as follows: 
1.  Model the diffusion of ganciclovir release from the Vitrasert® microcapsule into 
surrounding tissue 
2.  Optimize the properties of the microcapsule that has a constant rate of drug release for 
a given amount of time 
3.  Determine whether toxic levels of the drug would be obtained during usage. 
 
4.0 Project Schematics 
4.1 Assumptions 
To simplify our drug diffusion model in a reservoir microcapsule, we will be making the 
following the assumptions. 
1.  The microcapsule is cylindrically uniform and will be modeled as a cylinder shape. 
2.  Uniform properties throughout the tissue used in the model. 
3.  The drug will be released only from the top and bottom surfaces of the microcapsule. 
4.  There will be no angular variation in the drug diffusion, which results in a two-
dimensional axi-symmetry problem. 
5.  All of the drug released from the microcapsule is diffused directly into the tissue. Optimizing Release from Reservoir Microcapsules   7 
 
4.2 Geometry 
The geometry of our microcapsule model created in COMSOL is replicated in Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
Surrounding tissue 
Symmetric cross 
section 
Cross section of microcapsule to model 
Micro- 
capsule 
45
Figure 2. Diagram of the microcapsule and modeling parameters. 
5.0 Results and Discussion 
 5.1 Defining the Mesh 
In order to study the diffusive rate at which ganciclovir suspended in fluid is released from the 
Vitrasert®, a computational fluid dynamic (CFD) modeling program was used.  The CFD 
software, called COMSOL Multiphysics 3.3, enabled the creation of unstructured 
computational mesh that is well suited for incompressible flow and transport problems.  The 
mesh of the surrounding tissue and within the microcapsule was simulated in accordance with 
the mesh within the microcapsule wall.  There is a greater mesh density within the walls 
because these regions experience a greater fluctuation in the flux of the drug (see Figure 3).   
 
 
 
 
 
 
 
 
 
 
 
5.2 Qualitative Analysis 
Figure 3. Mesh diagram of microcapsule, microcapsule walls, and surrounding tissue. Number of elements in the 
microcapsule wall is 15,342. Optimizing Release from Reservoir Microcapsules   8 
 
The Vitrasert® reservoir microcapsule implant is designed to release an effective drug dosage 
to the tissue for a period up to 6 months.  To run our simulations, we obtained values from 
literature regarding the diffusivity of the retinal tissue, the microcapsule and its polymer wall in 
addition to the rate of elimination of ganciclovir in the tissue.  To produce a reasonably 
accurate model which describes the drug release of the Vitrasert®, we obtained accurate values 
for the initial drug dosage found in the current Vitrasert®.  These values are all detailed in 
Appendix C. 
 
The initial value condition (t=0) was simulated via COMSOL (see Figure 4) where a red region 
indicates high drug concentration and blue regions have very little or zero drug present.  Note 
that at time =0, no drug has diffused from inside the microcapsule into the wall. 
Figure 4. Contour plot of microcapsule, microcapsule wall, and surrounding tissue at initial time Optimizing Release from Reservoir Microcapsules   9 
 
Since it was difficult to find in literature the diffusivity value of the microcapsule wall, the 
simulation was run for approximately 270 days at a time step of 86400 and repeated with a one 
thousand-fold and ten thousand-fold decrease in the Dwall value.  Figure 5 shows the release 
profile of ganciclovir from the microcapsule into the tissue taking into account the diffusion 
and the elimination rates of the drug within the tissue.  In these figures, regions that exceed 
limits of the contour scale bar appear as white.   In Figure 5(A) and 5(B), the contour plots are 
shown for 2 and 30 days respectively, because after each of these days at its respective Dwall 
value, there was hardly any drug left in the tissue.  Too large of a diffusivity value in the 
microcapsule wall may be the culprit for such an occurrence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A  B 
C 
 
 
 
Figure 5. Contour plot of microcapsule, microcapsule wall, and surrounding tissue after (A) 2 days (B) 30 days and (C) 270 
days.  The corresponding diffusivity values of the microcapsule wall are (A) 2.8 X 10
-10 m
2/s, (B) 2.8 X 10
-13 m
2/s and (C) 2.8 
X 10
-14 m
2/s. All concentrations not in the range of 0.00078 mol/m
3 and 0.1567 mol/m
3 were shaded white. 
 
 Optimizing Release from Reservoir Microcapsules   10 
 
Concentration vs. Time
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
0
259200
518400
777600
1036800
1296000
1555200
1814400
2073600
Time, t (s)
C
o
n
c
e
n
t
r
a
t
i
o
n
,
 
c
 
(
m
o
l
/
m
^
3
)
Wall Diffusivity 2.8e-12
Wall Diffusivity 2.8e-11
Wall Diffusivity 2.8e-10
Figures 6 and 7 show that with a decrease in the value the wall diffusivity, the life of the 
microcapsule can be extended.  Comparison of the five diffusivity values ranging from 2.8 X10
-
10 m
2/s to 2.8X10
-14 m
2/s, a diffusivity of 2.8 x 10
-14 m
2/s was selected for our optimization 
m o d e l .   T h i s  i s  b e c a u s e  a t  t h i s  v a l u e ,  t h e peak concentration remains under any toxic 
concentration levels and show a sustained concentration over time.   
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Figure 6. Graph of concentration (mol/m
3) v. time (s) of ganciclovir in tissue for microcapsule wall diffusivity 
ranging from 2.8 x 10
-10 m
2/s to 2.8 x 10
-12 m
2/s over the course of 270 days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.0  
 
 
Figure 7. Graph of concentration (mol/m
3) v. time (s) of ganciclovir in tissue for microcapsule wall diffusivity 
ranging from 2.8 x 10
-13 m
2/s to 2.8 x 10
-14 m
2/s over the course of 270 days. 
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Sensitivity Analysis 
6.1 Diffusivity of Microcapsule Wall ‐ Dwall  
Sensitivity analysis was performed to see how the diffusivity of the microcapsule wall, Dwall, 
affects the average concentration of drug in the tissue after 270 days.  The sensitivity analysis 
was run using diffusivity values in addition to the five that were used to obtain the results.  
Figure 8 below depicts what would be expected when varying Dwall by orders of ten.   
Average Drug Concentration vs. Microcapsule Wall Diffusivity
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Figure 8. Graph of average concentration of drug in the tissue (mol/m
3) vs. diffusivity of microcapsule wall 
(m
2/s) at 270 days. 
 
 
A Dwall value of 2.80 x 10
-14 m
2/s is the optimal value for the largest average concentration of 
the drug in the tissue after at 270 days.  Values higher than this allow the drug to diffuse 
through the wall too quickly so concentration in the tissue is zero at this time.  At higher 
diffusivities, the capsule would be empty at this time.  Diffusivities lower than the optimal Dwall 
value show less significant changes when compared to values higher than the optimal Dwall 
value.  This can be attributed to slower diffusion of the drug through the microcapsule wall.  
The slower diffusion allows the drug to not deplete after 270 days; however, the average 
concentration of the drug in the tissue will not be as high.  If the diffusivity is too low, then 
diffusion of the drug through the microcapsule wall will be so slow that the concentration of 
the drug in the tissue will never reach any significant concentration to be effective.  Figure 10 
shows that drug diffusion through the microcapsule is very sensitive to Dwall.  It would be 
important to validate the value of Dwall through experimentation as any changes in this 
parameter could change the lifespan of the microcapsule. Optimizing Release from Reservoir Microcapsules   12 
 
 
6.2 Initial Concentration within Microcapsule 
A sensitivity analysis was performed on the initial concentration within the microcapsule for a 
Dwall value equal to 2.80 x 10
-14 m
2/s.  Because this Dwall value was determined to be the 
optimal value, it was not important to analyze the sensitivity of initial concentration with 
respect to the other Dwall values used.  For this sensitivity analysis, the effect of initial 
concentrations 10% and 20% larger and smaller was compared with the original initial 
concentration used in the model.  For each of these initial concentrations, the model was 
solved for a final time of 270 days and the average concentration of the drug in the tissue was 
determined.  The results are tabulated in Table 2 and depicted in Figure 9 below. 
 
Initial concentration 
(mol/m
3)  Avg. concentration at 270 days (mol/m
3) Percent  change 
195.2   3.75 x 10
-5   19.55  
219.6   4.20 x 10
-5   9.78  
244   4.66 x 10
-5   0 
268.4   5.18 x 10
-5   11.23  
292.8   5.60 x 10
-5   20.22  
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Table 1.  Average concentration of drug in the tissue at 270 days after varying initial drug concentration 
inside the microcapsule. 
  Figure 9. Graph of average concentration of drug in tissue (mol/m
3) vs. initial concentration of drug in 
microcapsule (mol/m
3) after 270 days.   Optimizing Release from Reservoir Microcapsules   13 
 
From the results, we found that the initial concentration appears to affect average 
concentration in a linear manner.  Therefore, 10-20% increase or decrease in initial 
concentration changes average concentration by approximately 10-20% as well.  More exact 
values for percent change are tabulated in Table 2 above.  These results show that while initial 
concentration does affect average concentration, it is not as sensitive of a parameter as Dwall.  
The initial concentration can be varied in experimentation if small changes in average 
concentration are desired. 
 
6.3 Microcapsule Wall Thickness 
A sensitivity analysis was performed on the microcapsule wall thickness for a Dwall value equal 
to 2.80 x 10
-14 m
2/s.  Because this Dwall value was determined to be the optimal value, it was 
not important to analyze the sensitivity of wall thickness with respect to the other Dwall values 
used.  For this sensitivity analysis, the affect of wall thickness up to 30% larger and up to 20% 
smaller was compared with the initial wall thickness used in the model.  For each wall 
thickness, the average concentration of the drug in the tissue was calculated at 270 days.  Table 
3 below tabulates the results of this analysis. 
 
Wall Thickness (mm)  Avg. concentration at 270 days (mol/m
3) Percent  change 
0. 28  4.47 x 10
-5 4.26 
0. 315  4.61 x 10
-5 1.23 
0.35  4.67 x 10
-5 0 
0.385  4.72 x 10
-5 1.25 
0.42  4.63 x 10
-5 0.78 
0.455  4.65 x 10
-5 0.44 
 
Table 2.  Average concentration of drug in the tissue at 270 days after varying the microcapsule wall 
thickness   
 
The above results show that the model is not sensitive to the thickness of the microcapsule wall 
at the optimal value for Dwall.  Even for a change as large as a 20% decrease and 30% increase 
in wall thickness, the percent change in average concentration is only 4.26% and 0.44% 
respectively.  This means that when creating the microcapsule, natural variations in wall 
thickness between microcapsules would not affect the overall ability of the microcapsule to 
deliver the drug to the tissue.   Optimizing Release from Reservoir Microcapsules   14 
 
 
7.0 Conclusion and Optimization Recommendations 
7.1 Optimization of Design 
Further testing was performed using COMSOL's animation feature to depict which regions are 
between the MEC and MTC for our drug.  This was accomplished by setting our contour 
graph's range between 0.00078361 mol/m
3 – 0.157 mol/m
3; this now shows our geometry in 
color in regions where the drug is effective, and in white when outside the range we want.  
Two preliminary videos were made for this test: one over 30 days (½ day time steps) with our 
specifications from last time.  It was seen that by 20 days, the tissue region within our target 
concentrations had already diminished.  A second video was created with a 10-fold reduction 
in diffusivity through the wall over 90 days (1 day time steps).  This showed that with proper 
tweaking of the wall, our drug easily affected a tangible volume of tissue over 3 months.  More 
importantly, it also confirms that our model is useful for design optimization.  These videos 
(and others, in the future) are available on CD format and are also available online: 
 
http://video.google.com/videoplay?docid=-5865080372626890235
http://video.google.com/videoplay?docid=-2173838320026871988
 
7.2 Problems Encountered 
 
Initially, our group spent a significant amount of time familiarizing ourselves with using 
COMSOL.  After working through several program tutorials in addition to the help of Vineet 
Rakesh, we were able to apply what we learnt in COMSOL to develop a working model for a 
first-order drug release from a microcapsule.  Several attempts were made in perfecting our 
model’s schematic drawing to produce quality results.  For example, we discovered how to 
rescale the color legend containing the contour colors so that it starts at 0 instead of some 
arbitrary negative value.  This allows us to obtain more realistic results of the drug diffusion 
process as well as to see ranges of effective drug concentration over a certain period of time.  
Moreover, we improved our model after learning how to set a flux = 0 at an interior boundary 
which is what we needed to represent the microcapsule wall that is impermeable to 
ganciclovir. 
 
One major problem that stumped us for a while was the generation of a negative concentration 
value after running our simulation at a certain t > 0.  We realize that this was only the case for Optimizing Release from Reservoir Microcapsules   15 
 
certain regions in the tissue.  Thus, in order to overcome such an error, all our calculated 
results and sensitivity analysis is a comparison using the average concentration found in the 
t i s s u e .   T hi s  w a y ,  a n y  ne g a t i v e  v a l u e s  wi l l  b e  o f f s e t  b y  m o re  a c c u r a t e  d r u g  c o n c e n t ra t i o n 
elsewhere in the tissue.   
 
After spending an arduous amount of time looking through literature for diffusivity values of 
microcapsule wall and coming up empty-handed, we decided to determine the optimal value 
through our model instead.  Using the knowledge that the Vitrasert® implant should last 6-8 
months, we were able to back calculate the necessary value for the wall diffusivity.  This value 
is particularly important because a change by a magnitude of 10 could result in shorter drug 
release duration causing patients suffering from CMV to receive more frequent implants.  
 
Lastly, we often experienced “not enough memory” and “not enough space” errors when 
defining our mesh or calculating a solution at a  l a r g e  t i m e  v a l u e .   T h i s  i s  p a r t i c u l a r l y  
frustrating as oftentimes these errors would crash the program forcing us to restart without any 
of our data saved.  To overcome the memory, we reduced the number of mesh elements within 
the microcapsule wall so that our model could still output a solution.  To prevent exceeding 
the storage space, a greater time step value was implemented in order to obtain solutions at 
greater time values.  However, by increasing the time step, many data points in between was 
left unrecorded.  Thus, without using faster PCs, these errors will remain limitations to using 
the COMSOL software for our modeling needs. 
 
7.3 Design Recommendations 
 
We offer two recommendations for further improvements that can be considered while using 
COMSOL to model a first-order drug delivery from a microcapsule: 
•  More computing power: This would allow for smaller time steps to be used, more 
storage space for data, obtain results in less time and thereby increasing overall 
accuracy of simulation. 
•  Model different geometries: While we modeled our microcapsule similar to that of 
the Vitrasert® which simplified the problem to a 2-D cylinder, we did not examine 
whether or not other geometries will produce a better constant drug release profile.  
Examining various geometries can be useful in determining the best shape for a 
microcapsule implant. Optimizing Release from Reservoir Microcapsules   16 
 
7.4 Conclusion 
With our simplified capsule geometry and basic diffusion with first order reaction model, we 
were able to optimize our capsule’s release profile such that a significant volume of 
surrounding skin was in the desired concentration window between the MEC and MTC for a 
prolonged period of time.  In fact, in our optimized case with diffusivity equal to 2.8X10-
14 
m
2/s, the drug was seen to persist for nearly 6 months, which matches literature values of 6 to 
8 months.  We conclude that our model is indeed sufficient for feasibility studies of 
microcapsules.  Companies wishing to test out different capsule designs could use our model in 
COMSOL as an initial check on whether the design is possible.  Building a more accurate 
model is possible but would require further experimentation and increased complexity.   
 
8.0 Appendix A: Mathematical Statement of the Problem 
 
8.1 Governing Equations 
Diffusion Equation for 2-D Transient Drug Delivery from microcapsule into tissue 
2
2
cc
D
tx
∂ ∂
=
∂ ∂
 
Diffusion Equation for 2-D Transient Drug Delivery within tissue 
2
2 A
cc
Dr
tx
∂∂
= −
∂∂
 
 
8.2 Boundary Conditions 
Microcapsule 
Assume that drug is only released from the top and bottom surfaces.  
•  On the left boundary:  species flux = 0 
•  On the right boundary: species flux = 0 
•  On the bottom boundary: species flux = 0 
 
Surrounding Tissue 
Assume drug concentration goes to 0 by the time it hits the edge of the tissue 
 
8.3 Initial Conditions 
•  Initial drug (ganciclovir) concentration in tissue = 0 mg/ cm
3 
•  Initial drug (ganciclovir) concentration in Vitrasert® = 4.5 mg/ cm
3 
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9.0 Appendix B: Mesh Convergence Analysis
9.1 Mesh Convergence 
In determining whether an appropriate mesh was selected for our model, we will show that by 
making a finer mesh, the average concentration of our drug delivered to the tissue will not 
significantly change.  Currently, our model is created such that by altering the number of 
elements in the mesh of the wall in which drug diffuses; the mesh in the tissue region and 
within the microcapsule will also conform by the same factor.  Hence, by illustrating the 
average drug concentration in the tissue at varying number of mesh elements within the 
capsule wall, we can determine an optimal and effective mesh necessary for obtaining a 
constant solution while using minimal computer memory. From our analysis in Figure 12, the 
number of elements chosen for our model is 15,342. 
 
 
 
 
 
 
 
 
 
 
 
Number of Elements vs. the Average Concentration of 
Drug Found in the Tissue
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Figure 12. Graph of the number of elements vs. the average concentration of drug in the tissue (mol/m
3). 
After 15,000 elements, the mesh can be seen to begin to converge since the plots approaches steady state. 
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10.0 Appendix C: Input Parameters 
 
Parameter Value 
Diffusivity of Tissue
8, Dtissue 5.1x10
-10 m
2/s 
Diffusivity of Microcapsule
8, Dmicrocapsule 2.8 x 10
-10 m
2/s 
Diffusivity of Microcapsule Wall, Dwall 2.8X10
-10 - 2.8X10
-14 m
2/s 
Rate of Elimination of Drug in Tissue
9, RA 0.00005 mol/m
3s 
Initial drug concentration in microcapsule
3, Co 244 mol/m
3
Table 3.  Summary of parameters and its associated values used by COMSOL in this simulation. Optimizing Release from Reservoir Microcapsules   19 
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